



Published in final edited form as:

Cancer Res. 2021 January 15; 81(2): 384–399. doi:10.1158/0008-5472.CAN-20-1488.

Frizzled-7 identifies platinum-tolerant ovarian cancer cells susceptible to ferroptosis

Yinu Wang¹, Guangyuan Zhao¹, Salvatore Condello², Hao Huang¹, Horacio Cardenas¹, Edward J. Tanner¹, JianJun Wei^{3,4}, Yanrong Ji⁵, Junjie Li⁶, Yuying Tan⁶, Ramana V. Davuluri⁵, Marcus E. Peter^{4,7}, Ji-Xin Cheng⁶, Daniela Matei^{1,4,8}

¹Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL

²Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN

³Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL

⁴Robert H. Lurie Comprehensive Cancer Center, Chicago, IL

⁵Division of Health and Biomedical Informatics, Department of Preventive Medicine, Northwestern University, Chicago, IL

⁶Department of Physics, Boston University, Boston, MA

⁷Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL

⁸Jesse Brown Veteran Affairs Medical Center, Chicago, IL

Abstract

Defining traits of platinum-tolerant cancer cells could expose new treatment vulnerabilities. Here, new markers associated with platinum-tolerant cells and tumors were identified using *in vitro* and *in vivo* ovarian cancer (OC) models treated repetitively with carboplatin and validated in human specimens. Platinum-tolerant cells and tumors were enriched in ALDH(+) cells, formed more spheroids, and expressed increased levels of stemness-related transcription factors compared to parental cells. Additionally, platinum-tolerant cells and tumors exhibited expression of the Wnt receptor *Frizzled 7 (FZD7)*. Knockdown of *FZD7* improved sensitivity to platinum, decreased spheroid formation, and delayed tumor initiation. The molecular signature distinguishing *FZD7*(+) from *FZD7*(-) cells included epithelial-to-mesenchymal (EMT), stemness, and oxidative phosphorylation-enriched gene sets. Overexpression of *FZD7* activated the oncogenic factor *Tp63*, driving upregulation of glutathione metabolism pathways, including glutathione peroxidase 4 (GPX4), which protected cells from chemotherapy-induced oxidative stress. *FZD7*(+) platinum-tolerant OC cells were more sensitive and underwent ferroptosis after treatment with GPX4

Corresponding Author: Daniela Matei, MD, Department of Obstetrics and Gynecology Medical Sciences, Feinberg School of Medicine Northwestern University, Chicago, IL, daniela.matei@northwestern.edu.

Author contributions: YW and DM designed the experiments; YW, GZ, SC, HH, JL, YT and JC performed experiments; GZ, YJ and RD completed bioinformatic analyses; YW, GZ, JL, MP and DM analyzed data; JW and ET provided specimens and edited the manuscript; YW, GZ, HC, MP, YJ, and DM wrote and edited the manuscript; JC and MP provided research reagents and valuable comments; DM provided funding for the study.

Conflicts of Interest: The authors have no conflicts of interest to declare.

inhibitors. *FZD7*, *Tp63*, and glutathione metabolism gene sets were strongly correlated in the OC Tumor Cancer Genome Atlas (TCGA) database and in residual human OC specimens after chemotherapy. These results support the existence of a platinum-tolerant cell population with partial cancer stem cell features, characterized by *FZD7* expression and dependent on *FZD7*- β -catenin-*Tp63*-*GPX4* pathway for survival. The findings reveal a novel therapeutic vulnerability of platinum-tolerant cancer cells and provide new insight into a potential “persister cancer cell” phenotype.

Keywords

Frizzled-7; platinum tolerance; platinum resistance; ovarian cancer; cancer stem cells; ferroptosis; glutathione peroxidase 4 (GPX4)

Introduction

Ovarian cancer (OC) is the leading cause of death from female gynecological cancers. Although initially a highly chemo-responsive tumor (1), most patients with OC experience tumor relapse and recurrent, resistant OC is fatal (2). “Persister” or drug-tolerant cells have been described as cells surviving cytotoxic drug exposure (3) and represent a reservoir for the outgrowth of drug-resistant clones. Recent studies in various cancers have reported the molecular signature of “persister” cells, including upregulation of stemness factors, mesenchymal-like gene expression, enrichment in glutathione peroxidase 4 (GPX4) and other genes related to lipid peroxidation, which antagonize ferroptosis allowing cells to survive after cytotoxic drug exposure (3–5). Small molecule inhibitors targeting GPX4 were shown to induce lipid peroxidation and eliminate tyrosine kinase receptor inhibitor tolerant cells through ferroptosis (3). It has been suggested that “persister” cells share characteristics with cancer stem cells (CSCs), but also have distinct traits. Specific markers to allow their identification and early targeting remain elusive. Here we sought to characterize the OC “persister” phenotype.

Our and other previous studies showed that while chemotherapy is effective at cytoreducing the mass of heterogeneous cancer cells, residual tumors persist and are enriched in CSCs (6, 7). Ovarian CSCs share some of the normal stem cells’ characteristics, including the ability to self-renew, differentiate, express specific stem cell surface markers (6, 8, 9), and exhibit enhanced tumor initiation capacity (TIC) (10). Importantly, ovarian CSCs possess a phenotype associated with drug resistance, including diminished apoptotic responses, increased efflux mechanisms and antioxidation defense (4, 8, 11, 12). The boundaries between stemness and platinum resistant (Pt-R) phenotypes remain blurry and, while an overlap exists, it is assumed that distinct pathways drive the two entities.

As platinum tolerant (Pt-T) cancer cells drive tumor relapse, we aimed to identify specific markers, by using *in vitro* and *in vivo* models of repeated exposure to the cytotoxic agent. We observed that Pt-T cells and tumors contained an increased ALDH⁺ cell population, expressing stemness related transcription factors (TFs), and able to form more spheroids compared to chemotherapy naïve cells. We identified the Frizzled 7 receptor (*FZD7*) as a novel cell surface marker significantly upregulated in the platinum tolerant cell population.

FZD7 knock down increased sensitivity to Pt, decreased spheroid formation, and inhibited TIC. *FZD7*(+) cells harbored a “persister cell”-like signature, including down-regulated genes associated to *DNA damage response*, upregulated *epithelial to mesenchymal (EMT) and stemness*, and decreased expression of genes associated with *oxidative phosphorylation*. Expression of the antioxidant enzyme, GPX4 was increased in *FZD7*(+) Pt-T cells, rendering them sensitive to treatment with GPX4 inhibitors. Mechanistically, *FZD7* caused activation of the transcriptional regulator, *Tp63*, which drove upregulation of glutathione metabolism genes, protecting cells from oxidative stress. In all, our results support the existence of a “persister” Pt-T cell population, sharing traits with CSCs, marked by upregulation of the receptor *FZD7* and harboring a dependency on *FZD7-β catenin-Tp63* mediated GPX4 expression and anti-oxidant activity.

Materials and methods.

Human specimens.

Deidentified high grade serous ovarian tumors (HGSOC) and associated malignant ascites were collected and processed fresh from patients who provided written informed consent. Tumor tissues were enzymatically dissociated into single cell suspensions and cultured as previously described (6, 8). A tissue microarray (TMA) was built from de-identified HGSOC specimens (n = 23) from patients who had undergone 3–6 cycles of platinum-taxane neoadjuvant chemotherapy (IRB approved CSR protocol #1247). Each specimen was entered in duplicate and fallopian tube epithelium (n=6) served as control. Patients’ characteristics are in Table S1. Human subject studies were conducted in accordance with the Declaration of Helsinki and approved the institutional review board (Northwestern University IRB#: STU00202468).

Cell lines and culture conditions.

SKOV3 and OVCAR3 cells were purchased from the American Type Culture Collection (ATCC). OVCAR5 cells were a generous gift from Dr. Marcus Peter, Northwestern University, COV362 cells were from Dr. Kenneth Nephew, Indiana University, immortalized human fallopian tube luminal epithelial cells (FT190) were from Dr. R. Drapkin of University of Pennsylvania (13). PEO1 and PEO4 cells were from Sigma Aldrich. Cell culture conditions are in Supplemental Material (SM). Low passage cells were used and all cell lines were tested to be pathogen and *Mycoplasma* negative (Charles River Research Animal Diagnostic Services).

Chemicals and reagents.

RSL3 was purchased from Fisher Scientific (Cat# 611810). ML210 (Cat# SML0521), cisplatin (Cat# 1134357), and carboplatin (Cat# C2538) were from Sigma-Aldrich. WNT3a was from Fisher Scientific (Cat# 5036WN010CF, R&D Systems), and IWR-1-endo was from Santa Cruz (sc-295215A).

***In vitro* development of Pt-R cells:** To generate Pt-T OC cells, SKOV3, OVCAR5, COV362, and OVCAR3 cells were treated with 3 or 4 repeated or increasing doses of cisplatin or carboplatin for 24 hours. Surviving cells were allowed to recover for 3 to 4

weeks before receiving the next treatment. Changes in resistance to platinum were estimated by calculating half maximal inhibitory concentration (IC₅₀) values as described below.

In vivo experiments: Animal studies were conducted according to a protocol (# IS00003060) approved by the Institutional Animal Care and Use Committee of Northwestern University and are described in SM. Experiments using PDX tumors were performed in the Developmental Therapeutics Core (DTC) of the Lurie Cancer Center, as previously described (14) and following a similar protocol (see SM).

Isolation of tumor cells.

Tumors from patients or xenografts were minced and enzymatically dissociated in Dulbecco's modified Eagle's medium/F12 (Thermo Fisher Scientific, Ref# 11320) containing collagenase (300 IU/ml, Sigma-Aldrich, Cat#C7657) and hyaluronidase (300 IU/ml, Sigma-Aldrich, Cat# H3506) for 2–4 hours at 37°C. The tissue digest was passed several times through a 16–18G needle using Cell Stripper (Corning, Cat# 25-056-CI) to dissociate remaining cell aggregates. Red blood cell lysis used RBC lysis buffer (BioLegend, Cat#420301), followed by DNaseI (Sigma Aldrich, Cat# DN25) treatment and filtering through a 40µm cell strainer (Fisher Scientific, Cat#NC0147038) to yield single cell suspension.

Aldefluor assay and flow cytometry.

Aldehyde dehydrogenase (ALDH) activity was measured using an Aldefluor assay kit (Stemcell Technologies, Cat#01700, Cambridge, MA, USA) following the manufacturer's instructions and as described previously (6).

Cell survival assay.

Cell survival was measured with a Cell Counting Kit 8 (CCK8, Dojindo Molecular Technologies, Cat# CK04, Rockville, MD, USA), following the manufacturer's protocol. Absorbances (450 nm) were measured with a microplate reader (BioTek ELX800, BioTeK, Winooski, VT).

Detailed protocols for **spheroid formation assay; clonogenic assay, RNA extraction, quantitative Rt-PCR, western blotting and IHC** are included in SM. Primers are included in Supplementary Table S2.

Extreme limited dilution assay.

A serial dilution of OVCAR5_shControl or OVCAR5_shFZD7 cells (5, 10, 50, 100, 500, 1000, and 5000 cells) were sorted by FACS directly into 96-well low-attached plates and cultured in MammoCult medium for 14 days as described above. Each dilution included 10 replicates. The total number of wells containing spheroids for each dilution were counted. The CSC frequency and statistical significance were determined using ELDA software at <http://bioinf.wehi.edu.au/software/elda/>(15).

Half maximal inhibitory concentration (IC₅₀).

The IC₅₀ values of the various treatment compounds were determined by the CCK8 assay as described in SM. IC₅₀ values were determined by logarithm-normalized sigmoidal dose curve fitting using Prism 6 software (GraphPad Software Inc., San Diego, CA).

Lipid peroxidation assay: Intracellular lipid peroxidation was determined by a Lipid Peroxidation Assay (Sigma-Aldrich, Cat# MAK085) following the manufacturer's protocol (see SM).

Oxygen consumption rate.

Cells were seeded on 96-well plates at 100,000 cells/well and incubated overnight. 10 μ L of extracellular O₂ consumption reagent (Oxygen Consumption Rate Assay kit, Abcam Cat#197243) were added to each well, and fluorescence was measured with a plate reader (SpectraMax i3X, Molecular Devices, San Jose, CA, USA) at 3 min intervals for 180 min at excitation/emission = 380/650 nm. Alternatively, oxygen consumption was measured using a Seahorse assay. Briefly, OVCAR5 shControl and shFZD7 cell lines were seeded in Seahorse 96-well microplate (Agilent, Cat#102416-100, Santa Clara, CA, USA) at a density of 10-80K per well. After incubation overnight, oxygen consumption was measured and calculated by Seahorse XFe96 Analyzer (Agilent, Santa Clara, CA, USA).

BODIPY staining for lipid peroxidation.

Cells were treated as described in SM. After treatment, cells were stained with BODIPY 581/591 C11 (5 μ M) for an hour at 37°C, washed with PBS, and fixed with 4% PFA on ice for 30 mins. The mean fluorescence intensity (minimum of 10,000 events per condition) was measured by FACS (LSR Fortessa, BD, Franklin lake, NJ). BODIPY emission was recorded on channels for FITC at 520nm and PE at 580nm. The data were displayed as histograms and mean fluorescence intensity of FITC was calculated.

Intracellular ROS levels were measured by monitoring the oxidation of cell permeable 2',7'-dichlorofluorescein diacetate (DCFHDA, Sigma-Aldrich) at excitation and emission wavelengths of 480 and 535 nm. 150,000 cells cultured in 35 mm glass bottom dish were treated with 1 or 2 μ M ML210 alone or with 800nM DFOA for 24 hours. Cell cultures were then treated with 10 μ M DCFDA (Abcam, Cat#ab113851) for 15 minutes to detect ROS level through confocal fluorescence microscopy. ROS level was measured as integral fluorescence intensity normalized by the cellular area in a frame (n=15 frames) using ImageJ (<https://imagej.nih.gov/ij>).

RNA sequencing (RNA-seq) and data analysis.

The RNA-seq libraries (n=3 per experimental group) were prepared using the NEBNext Ultra II RNA library prep kit from Illumina (New England Biolabs Inc., Ipswich, MA, see SM). Trimmed reads were aligned to the ENSEMBL human genome version GRCh38 using STAR (2.5.2)(16) and SAMtools (17). Mapped reads were then counted using HTSeq (18). Differentially expressed genes were determined by exact test analysis followed by multiple hypothesis correction using false discovery rate (FDR) on the edgeR package (19). Genes with FDR < 0.05 were considered differentially expressed. Normalized counts for all genes

were ranked and subject to Gene Set Enrichment Analysis (20). Data are deposited in GEO (GSE148003).

Analysis of data from The Cancer Genome Atlas (TCGA) included correlation analysis between gene pairs and survival analysis, described in SM.

Statistical analyses of experimental data.

All data are presented as mean values \pm SD of triplicate measurements. Two-tailed Student's *t*-test or ANOVA (one-way or two-way) were used to determine effects of treatments. $P < 0.05$ were considered significant. All analyses were performed using Prism 6.0 software (GraphPad Software).

Results

Stemness and ferroptosis signatures are enriched in platinum-tolerant cancer cells.

Pt-T OC cells were generated through repeated *in vitro* exposure of OC cell lines (OVCAR3, OVCAR5, COV362 and SKOV3) to platinum at IC₅₀ concentrations (Supplemental Figure S1A), while Pt-R xenografts were obtained by treating tumor harboring mice with carboplatin for 4–6 weekly cycles (Figure S1B). Repeated platinum exposure of OC cells induced a stable phenotype, with at least 2-fold increase in platinum IC₅₀ (Supplementary Table S3) compared to parental chemotherapy naïve cells. Pt-T OC cells were enriched in ALDH(+) cells (Figure 1A and S2A), formed increased numbers of spheroids (Figure 1B and S2B), and contained cells expressing CSC-related TFs (*Oct4*, *Nanog* and *Sox 2*) (Figure 1C and S2C–D) compared to controls. RNA sequencing compared Pt-R vs. parental naïve cells, with transcriptomic signatures revealing enrichment in *stemness* associated gene sets (Figure 1D and S2E). Similar observations were made *in vivo*, including in carboplatin treated OVCAR3 (Figures 1E–F) and SKOV3 (Figure S2F) xenografts. ALDH(+) cells were enriched (Figure 1E) and stemness associated genes (*ALDH1A1*, *Oct4*, *Nanog* and *Sox 2*) were upregulated (Figure 1F and S2F) in carboplatin-treated compared to PBS-treated xenografts, as we noted previously (6, 7).

Given the possibility that CSCs would be more resistant to chemotherapy due to upregulated anti-redox mechanisms (11) and considering a recently proposed association between oxidative stress and ferroptosis, a new form of cell death triggered by oxidized lipids, we examined a gene set related to “ferroptosis” (21) in Pt-T compared to parental OC cells. Clear differences including upregulated genes involved in glutathione metabolism and anti-oxidant defense mechanisms were observed in Pt-T OC cells vs. chemotherapy-naïve cells (SKOV3, Fig. 1G and OVCAR5, Fig. S2G). Interestingly, this molecular signature was observed in HGSOC cells with higher baseline resistance to platinum (IC₅₀ >5 μ M; COV362, OVCAR8, SNU119, and OVCAR4) compared with cells more sensitive to platinum (IC₅₀ <5 μ M; TYKNU, IGROV1, OVCAR3; Fig S2H) (7, 22), suggesting the pathway is a common signature of Pt resistant cells. The selenoprotein glutathione peroxidase 4 (*GPX4*), a key protein regulating anti-oxidant response, was among the upregulated genes in Pt-T cells. GPX4 inhibitors impede anti-oxidant defense mechanisms and promote death of cells dependent on this pathway (3). Indeed, Pt-R OC cells were more sensitive to the GPX4

inhibitor, ML210, compared to control cells (SKOV3, Fig. S3A; OVCAR5, Fig. S3B; COV362, Fig. S3C). ML210 induced inhibition of colony formation was inhibited by the iron chelator deferoxamine (DFOA), consistent with induction of a ferroptosis phenotype (Figs. S3A–C). Furthermore, primary OC cells derived from malignant ascites from patients with Pt-R OC, were found to be dependent on GPX4, as ML210 potentially reduced colony formation in these cells (Fig. 1H), this inhibition being rescued by DFOA.

ML210 caused increased oxidized membrane lipids levels, as measured by flow cytometry using the C11-BODIPY dye in Pt-T cells compared to naïve cells, supporting increased susceptibility to ferroptosis of Pt-R OC cells (SKOV3 and OVCAR5, Fig. 1I; COV362, Fig. S3D). Additionally, Pt-T SKOV3 cells were more sensitive to ML210 compared to parental cells (IC₅₀ of 224nM and 342nM vs. 889nM, Figures 1J, Fig. S3E–F). Primary OC cells derived from malignant ascites associated with Pt-R OC, displayed resistance to platinum *in vitro* (Figures 1K–L, left panels; IC₅₀ of 82μM and 16.52μM), and responded to low doses of the GPX4 inhibitors, ML210 (Figures 1K–L, right panels; IC₅₀ of 37.20nM and 62.36nM) and RSL-3 (Figure S3G–H, IC₅₀ of 14.20nM and 17.72nM). Trypan blue staining of parental and Pt-T SKOV3 and OVCAR5 cells treated with ML210 showed that the inhibitor induced more cell death in resistant OC cells ($p < 0.05$, Figures S3I–J). These results derived from multiple *in vitro* and *in vivo* OC models, including primary human cancer cells, support the existence of a “persister cell” phenotype induced by Pt, sharing partial stemness characteristics, and highly susceptible to ferroptosis.

Frizzled 7 (FZD7) is upregulated in Pt-T OC cells and tumors.

To identify potential markers linked to the “persister” phenotype, an RT-PCR based platform representing 90 cancer stemness associated genes was used. A number of known CSC markers were found to be upregulated in the Pt-T cells (*CD44*, *PROM1*, *SOX2*), along with membrane transporters known to be associated with Pt resistance (*ABCG2*, *ABCB5*), and regulators of EMT (*TGFBR1*, *SNAI1*, *BMP7*, *TWIST 1* and *2*, *SNAI 1* and *2*, see Table S4). Among transcripts representing membrane proteins, which could potentially be used as novel markers, *FZD7*, a transmembrane receptor involved in canonical Wnt/β-catenin/TCF and non-canonical Wnt/planar cell polarity (PCP) signaling (23, 24), was one of the top highly expressed transcripts (> 8-fold) in Pt-R compared to control cells (Table S4 and Figure S4A). Increased *FZD7* expression levels were confirmed in Pt-T models (SKOV3, OVCAR5, and OVCAR3) generated as described, compared to control cells at *mRNA* (Figure 2A) and protein level (Figure 2B), but also in Pt-R PEO4 cells compared to sensitive PEO1 OC cells, an isogenic cell line pair, derived from the same patient at different times during the disease course (25) (Figs. 2C–D). Likewise, *FZD7 mRNA* expression levels were upregulated in platinum treated SKOV3 (Fig. 2E) and OVCAR3 (Fig. 2F) xenografts compared to vehicle-treated tumors.

Flow cytometry was used to determine whether a *FZD7* high (*FZD7*⁺) cell population is detectable. *FZD7*⁺ cells were detected among cells dissociated from primary OC, previously untreated with chemotherapy, and represented ~ 3% of all cells (Figure 2G). In OC cell lines, *FZD7*⁺ cells were identified as a distinct sub-population representing ~25–35% of cells (SKOV3, OVCAR5 and COV362; Figure 2H). Additionally, the *FZD7*⁺ cell

population was detectable and was enriched in Pt-T compared to parental cells (SKOV3, OVCAR5, COV362; Figure 2H), suggesting that this cell membrane receptor may be a marker of “persister” cells, pre-existing in un-selected cell populations prior to Pt exposure, and enriched after exposure to the drug.

Further, we used patient derived xenografts (PDX) generated from newly diagnosed HGSOc (14), which were treated weekly with carboplatin. After initial response, recurrent tumors emerged (Figure 2I), which were enriched in ALDH (+) cells (Fig. S4B), CSC-related TFs (*Sox 2*, *Nanog*, *Oct4*), as well as *ALDH1A1* and *ALDH1A2* (Figure 2J). *FZD7* expression levels were upregulated at *mRNA* (Figure 2K) and protein level (Figure 2L), as measured by immunohistochemistry (IHC) in Pt-T PDX vs. control. Next, IHC assessed *FZD7* expression in primary HGSOc specimens and in tumors collected after 3–6 cycles of neo-adjuvant chemotherapy, containing surviving cells after standard platinum-taxane treatment, which are presumably Pt-T. Patients’ characteristics are included in Supplementary Table S1. Increased *FZD7* staining intensity (measured as H-score) was observed in cancer cells residual after chemotherapy in these specimens (n = 23), when compared to chemotherapy-naive tumors (n = 117, $p < 0.01$) (26) and to fallopian tube epithelium (control n = 6, Figure 2M, $p < 0.05$).

Functional role of FZD7 in OC cells.

FZD7(+) and *FZD7*(-) cells were FACS sorted from cell lines and human tumors. Differences in *mRNA* expression levels between *FZD7*(+) and *FZD7*(-) cell are shown in Figure 3A. *FZD7*(+) OC cells were less sensitive to cisplatin (CDDP) (Figures 3B–D; $p < 0.05$), supporting that the receptor marks a Pt-T population. Additionally, *FZD7*(+) cells formed spheroids more efficiently compared to *FZD7*(-) cells (Figure 3E–F, $p < 0.01$), and expressed higher levels of stemness associated TFs (SKOV3, Fig. 3G, OVCAR5, Fig. 3H; COV362, Fig. 3I; $p < 0.05$), supporting that they share stemness-related features.

To further examine its functions, the receptor was knocked-down (KD) by stable transduction of shRNA or was transiently overexpressed. Decreased *FZD7 mRNA* expression was confirmed by Q-RT-PCR in SKOV3 and OVCAR5 cells transduced with two shRNA sequences targeting the receptor (Figs. 4A–B). *FZD7* KD decreased spheroid formation (Figs 4A–B) and expression of stemness associated TFs (Figure 4C and S5A). *In vitro* serial limited dilution assay showed that receptor KD decreased stem cell frequency, as calculated by the ELDA software (27) in *FZD7* KD vs. control cells, ($p = 0.034$, Fig. S5B). Likewise, *FZD7* KD in Pt-T SKOV3_CDDP cells (Fig. S5C) decreased sphere formation (Fig. S5D). Stable *FZD7* KD in primary Pt-R tumor cells caused decreased expression levels of the stemness-associated gene *ALDH1A1* (Figures 4D–E). Conversely, transient overexpression of *FZD7* (Figs. 4E–F) promoted proliferation of SKOV3 and OVCAR5 cells as spheres (Fig. 4G) and increased expression of stemness associated TFs (Figure S5E–F). *FZD7* KD decreased IC_{50} to cisplatin by ~ 2-fold (SKOV3, Fig. 4H; SKOV3_CDDP, Fig. 4I; Fig. S5G–H); while the receptor’s overexpression increased Pt resistance (Fig. 4J; Fig. S5I).

To test the effects of *FZD7* to tumor growth, a subcutaneous (s.c.) xenograft model was used. *FZD7* KD in OVCAR5 cells delayed tumor initiation (sh-control 9.8 ± 4 days. vs. sh-*FZD7* 25.3 ± 4.9 days, Figure 4K, $p < 0.0001$) and decreased tumor size (Fig. S5J) and tumor

weight (0.80 ± 0.41 g vs. 0.14 ± 0.15 g, $p = 0.04$, Fig S5K, $n = 4/\text{group}$). FZD7 KD in xenografts was confirmed by IHC (Figure S5L). ALDH (+) cells ($16.5 \pm 6.5\%$ vs. $5.9 \pm 1.8\%$, $p = 0.05$; Fig. 4L, $n = 3$) and spheroid forming ability (Fig. 4M, $p = 0.02$) were decreased in cells dissociated from FZD7 KD vs. control xenografts. Further, to test the effects of FZD7 KD to tumor initiation, an *in vivo* serial limited dilution assay was carried out by using 2,500; 5,000; and 10,000 FZD7 KD and control cells. FZD7 KD significantly inhibited TIC (Figure 4N) and reduced stem cell frequency, as calculated by the ELDA software (Figure 4O). Combined, these results support that FZD7 is linked to stemness and chemo-resistance.

Molecular signatures of FZD7(+) cancer cells: Gene signatures distinguishing FZD7(+) vs. FZD7(-) cells; ovarian CSCs (ALDH⁺CD133⁺) vs. non-CSCs (ALDH⁻CD133⁻), and Pt-T vs. platinum-naïve OVCAR5 cells were examined and integrated (Figure 4P). FZD7(+) and (-) were sorted by FACS (Fig. S5J). Ovarian CSCs and non-CSCs were FACS-sorted by using dual stem cell markers, CD133 and Aldefluor activity (Fig. S5M–N). There were 666 differentially expressed genes (DEG) shared between FZD7(+)/FZD7(-) and CSCs/non-CSCs datasets, 5404 DEGs being unique to CSCs and 536 DEGs unique to FZD7(+) cells (Figure 4P). Additionally, there were 927 DEGs overlapping between FZD7+/FZD7- and resistant/parental cells, 10019 DEGs unique to the Pt-T cells and 275 genes uniquely associated with FZD7(+) cells (Figure 4P). Overlapping DEGs between FZD7+/FZD7- and OCSC/non-OCSCs were enriched in *Cancer Stem Cell*, but enriched *DNA Repair* signatures between FZD7+/- and resistant/parental cells (Fig. S6A–B). Additionally, FZD7(+) vs. FZD7(-) cells displayed signatures enriched in *stemness* (Fig. S6C), *EMT* (Fig. S6D) and *downregulated DNA damage response* genes (Fig. S6E). Together, these data suggest that FZD7(+) cells possess both shared, but also distinct features, relative to stemness and chemo-resistance, consistent with the phenotypes described above. Importantly, *mitochondrial and oxidative phosphorylation* gene sets were enriched among DEGs distinguishing FZD7(+) vs. FZD7(-) cells (Fig. S6F–H) and Ingenuity Pathway Analysis (IPA) identified *Oxidative Phosphorylation* and *Mitochondria Dysfunction* as the top enriched pathways in FZD7(+) cells, suggesting that the receptor marks a cell population harboring altered oxidative stress responses.

FZD7 marks a cell population enriched in GPX4.

Given that GPX4, an antioxidant enzyme which reduces reactive oxygen species (ROS), preventing formation of toxic lipid peroxides (28, 29), has been implicated in maintenance of normal mitochondrial function and oxidative phosphorylation (3, 28), we examined whether *FZD7* expression impacted *GPX4* expression and function in Pt-T OC cells. *GPX4* levels were significantly increased in FACS sorted FZD7(+) vs. FZD7(-) cells derived from SKOV3, OVCAR5, COV362 cells or cancer cells dissociated from human tumors (Fig. 5A, $p < 0.05$). Furthermore, *FZD7* KD by shRNA in OVCAR5 and SKOV3 cells resulted in repressed *GPX4 mRNA* (Fig. 5B, $p < 0.001$, and Fig S7A, $p < 0.05$) and protein expression levels (Fig. 5C). GPX4 expression was decreased in Pt-T SKOV3 cells (Fig. 5D) and in primary Pt-R OC cells (Fig. 5E) transduced with shRNA targeting *FZD7*. Conversely, *FZD7* overexpression induced increased GPX4 *mRNA* and protein expression levels (Figs. 5F–H).

Furthermore, *GPX4* and *FZD7* mRNA expression levels were coordinately upregulated in Pt-T models, including Pt-T vs. parental cells (SKOV3, OVCAR5, Fig. 5I, $p < 0.05$), Pt-T xenografts (Fig. 5J, $p < 0.05$) and PDXs (Fig. 5K, $p < 0.01$). Increased *GPX4* expression in Pt-T PDX vs. controls was confirmed by IHC (Fig. 5L). IHC examined GPX4 in HGSOc specimens collected after neo-adjuvant chemotherapy, noting increased GPX4 staining in these residual tumors ($n = 23$) when compared to fallopian tube epithelium, Fig. 5M, $p = 0.02$). Together, the results confirm a positive correlation between *FZD7* and *GPX4* expression in OC cells and in Pt-T models, supporting that *FZD7*(+) cells have increased anti-oxidant capacity. To confirm the functional relevance, *GPX4* enzymatic activity was measured by using the malondialdehyde (MDA) assay, which quantifies intracellular lipid peroxide levels. Lipid peroxides were found to be increased in *FZD7*KD vs. control cells (Fig. 5N, $p < 0.05$) and decreased in OC cells overexpressing *FZD7* (Fig. 5O, $p < 0.05$) supporting that *FZD7*(+) cells clear these toxic products more effectively, due to higher levels of *GPX4*.

GPX4 participates in regulation of intra-cellular redox states by utilizing glutathione (GSH) as the critical antioxidant (21). GSH is synthesized from glutamate-cysteine under the action of glutamate-cysteine ligase (GCL) (21). The cycling of reduced GSH to oxidized glutathione disulfide (GSSG) removes ROS derived from hydrogen peroxide and lipid hydroperoxides through various glutathione peroxidases (GPXs), including *GPX4* (21). GSH recycling from GSSG is catalyzed by glutathione reductase (GSR), using NADPH, whose synthesis is regulated by isocitrate dehydrogenase 2 (IDH2) (21). *FZD7*KD decreased the expression levels of multiple genes in this pathway, including *GPX2*, *GSS*, *IDH2*, *GSR*, *GCL* and *SLC7A11* (OVCAR5, Fig. 6A and SKOV3, Fig. S7B). Conversely, *FZD7* overexpression caused increased expression levels of *GSS*, *GSR*, *GCL* and *SLC7A11* (OVCAR5, Fig. 6B and SKOV3, Fig. S7C), suggesting a significant direct correlation between *FZD7* and glutathione metabolism related genes.

FZD7 Marks a Cell Population Susceptible to GPX4 Inhibitors: Given the correlations between *FZD7*, upregulated in Pt-T cells, and *GPX4*-mediated cellular redox maintenance, we hypothesized that inhibition of this axis will eliminate resistant cells. Small molecule inhibitors of *GPX4* have been shown to increase cellular oxidative stress and induce ferroptosis (3, 30–32). Thus, we examined the sensitivity of OC cells with high vs. low *FZD7* expression levels to *GPX4* inhibitors, ML210 and RSL3 (3, 32, 33). *FZD7*(+) sorted cells were more sensitive to the *GPX4* inhibitor ML210 compared to *FZD7*(-) cells (OVCAR5, Fig. 6C; COV362, Fig. 6D, SKOV3, Fig. S7D). *FZD7*KD in OVCAR5 and SKOV3 cells also slightly reduced sensitivity to *GPX4* inhibitors (Fig. 6E; Fig. S7E), while *FZD7* overexpression slightly increased sensitivity to ML210 compared to vector-transduced cells (Fig. 6F; Fig. S7F).

Through its anti-oxidant function, *GPX4* protects mitochondria from damage, maintaining normal oxidative phosphorylation. To test whether these processes were altered in *FZD7*(+) vs. *FZD7*(-) cells, as a consequence of differential *GPX4* expression, oxygen utilization was measured by using fluorescence labeled oxygen uptake assay and the seahorse assays. *FZD7*KD resulted in decreased oxygen uptake (Fig. S7G) and consumption rate (Fig. S7H), supporting the role of this pathway maintaining normal mitochondrial function.

Additionally, intracellular ROS levels, quantified by DCFHDA staining were decreased in *FZD7* KD cells compared to controls (Fig. 6G). As increased ROS levels contribute to oxidation of polyunsaturated lipids, leading to ferroptosis, C11-BODIPY staining was used in cells expressing different levels of *FZD7* and/or exposed to GPX4 inhibitors. Oxidation of the polyunsaturated butadienyl portion of the dye in the presence of ROS is reflected in a shift of the fluorescence emission peaks from red to green, a hallmark of ferroptosis. The mean green (FITC) fluorescence intensity caused by oxidized lipids was decreased in cells overexpressing *FZD7* and increased in *FZD7* KD cells (Fig. 6H), consistent with increased susceptibility to ferroptosis of *FZD7*(+) cells. ML210-induced increase in fluorescence was higher in SKOV3 and OVCAR5 cells overexpressing *FZD7* compared to controls and decreased in *FZD7* KD cells (Fig. 6I–J). Likewise, baseline and ML210 induced intracellular ROS levels (rescued by DFOA) were higher in control vs. *FZD7* KD OVCAR5 cells (Fig. 6K). Collectively, the data suggest that cells marked by *FZD7* are more susceptible to ferroptosis and could be eliminated by targeting GPX4.

FZD7 regulates GPX4 expression and glutathione metabolism by activating canonical β catenin/p63 pathway.

As a classical Wnt receptor, *FZD7* participates in both canonical β -catenin and non-canonical signaling. One of the known β -catenin targets is the transcription factor *p63*, directly transactivated by the TCF/LEF complex (34). Its most common isoform, NTP63, lacking its N-terminus domain, has been implicated in maintaining intracellular redox homeostasis by regulating genes involved in glutathione metabolism, including GPX4 (21). We therefore hypothesized that in Pt-T OC cells, *FZD7* could alter glutathione metabolism and protect OC cells from oxidative stress, through activation of β -catenin/TP63 signaling. *Tp63* expression was upregulated in Pt-R PDX (Fig. 7A) and OC cells compared to controls (Fig. S8A). *Tp63* expression was higher in *FZD7*(+) vs. *FZD7*(-) cells derived from SKOV3, OVCAR5, COV362 and human HGSOC (Fig. 7B) and *FZD7* KD caused decreased *Tp63* expression in OVCAR5 (Fig. 7C–D) and SKOV3 cells (Fig. S8B and Fig. 7D), while *FZD7* overexpression led to increased *Tp63* expression (Figs. 7E–G) at *mRNA* and protein levels. To demonstrate that the correlations between *FZD7*, TP63, and GPX4 were dependent upon the engagement of β -catenin, we used Wnt3A stimulation and the β -catenin inhibitor IWR-1-endo. Stimulation with Wnt3A induced p63 and GPX4 expression in control, but not in *FZD7* KD cells, while treatment with IWR-1-endo inhibited the expression of both p63 and GPX4 (Figure 7H, OVCAR5 and S8F, SKOV3). Similar observations were made when *FZD7* was overexpressed (Figure S8F), supporting that GPX4 upregulation is directly regulated by β -catenin.

Lastly, to determine whether *FZD7* regulates GPX4 expression by altering *Tp63* function, the effects of *Tp63* knockdown on GPX4 expression in cells expressing high vs. low levels of *FZD7* were tested. Overexpression of *FZD7* and KD of *p63* in OVCAR5 cells were confirmed at *mRNA* level (Fig. 7I–K; SKOV3, Fig S8C–E). *GPX4* upregulation induced by *FZD7* overexpression was abrogated in cells in which *p63* was KD (Fig. 7K; SKOV3, Fig S8E), supporting that this TF, engaged by β -catenin, downstream of *FZD7*, is an important regulator. Interestingly, *Tp63* KD caused reduced expression of *FZD7* in OC cells transfected with either control vector or *FZD7*, indicating a feedback regulatory role of *Tp63*

on *FZD7*. These experimental results were validated by examining the TCGA HGSOV database (35). *FZD7* and *Tp63* expression levels were positively correlated (Fig. 7L, $r = 0.278$, $p < 0.0001$) and *Tp63* expression was positively associated with expression levels of genes related to glutathione metabolism, including GSS, GCLC and SLC7A11 (Fig. S8G–I, $p < 0.01$). Higher *Tp63* expression levels were also significantly associated with poor overall survival in this patient cohort (Fig. 7M, $p = 0.0431$). In all, our results support the existence of a “persister” cell population, marked by *FZD7*, metabolically characterized by increased glutathione dependent anti-oxidant circuits and susceptible to ferroptosis. A potential mechanism leading to upregulation of GPX4 in platinum-tolerant OC cells marked by *FZD7* is engagement of *Tp63*, trans-activated by β -catenin downstream of this receptor (Figure 7N).

Discussion:

Our data support that a Pt-T (“persister”) cancer cell population serving as a reservoir for resistant tumors, shares common features with CSCs and is characterized by *FZD7* expression. We demonstrate that the survival of these cells is dependent on an active *FZD7*- β -catenin-*Tp63*-GPX4 pathway, which renders these cells susceptible to inducers of ferroptosis. Our findings have several implications.

First, we identified *FZD7* as a receptor enriched in Pt-T cancer cells and tumors. *FZD7* is a transmembrane receptor which transduces signals involved in both the canonical and non-canonical Wnt pathways (36). Previous data indicated that *FZD7* plays essential roles in stem cell biology and cancer (37). In breast and hepatocellular carcinoma, *FZD7* has oncogenic functions, promoting cell proliferation, migration, and invasion (24, 38–41). Here we show that *FZD7* marks a population representing ~2–25% cells in Pt-T cell lines or tumors. The receptor’s KD sensitized OC cells to platinum and its overexpression rendered cells resistant. Our group previously identified *FZD7* as a receptor facilitating interaction of ovarian CSCs with the tumor niche (42) and the current findings corroborate the link between this receptor and cancer stemness. *FZD7*(+) cells were shown to proliferate more robustly as spheres, to express higher levels of stemness associated TFs and display enhanced TIC. Interestingly, a related receptor, *FZD10*, was recently linked to PARP inhibitor resistance (43). Thus, it is likely that activation of the Wnt pathway through activation of one or more *FZD* receptors contributes to emergence of resistance to DNA-damaging agents.

Secondly, we report that *FZD7* marks a population of cells highly susceptible to ferroptosis. Ferroptosis is a newly described type of cell death distinct from apoptosis and necrosis (44) characterized by iron-dependent accumulation of ROS resulting in increased lipid peroxidation and eventually leading to cell death (33). Ferroptosis is dependent on NADPH/H(+), polyunsaturated fatty acid metabolism, and the mevalonate and glutaminolysis metabolic pathways (31). Class 1 (system Xc(–) inhibitors) and class 2 (GPX4) inhibitors are small-molecules that induce ferroptosis (44). Here we observed that *FZD7*(+) platinum tolerant cells were highly sensitive to ferroptosis induced by small molecules targeting GPX4. Tyrosine kinase inhibitor-tolerant cells have been reported to be sensitive to

ferroptosis (3); however, no markers to identify cells prone to ferroptosis have been described.

Thirdly, we found GPX4 to be significantly upregulated in Pt-T cells, xenografts, PDXs, and ovarian tumors residual after neoadjuvant chemotherapy. GPX4 detoxifies lipid peroxides (L-OOHs) by converting them to corresponding alcohols (L-OH), preventing the buildup of toxic, membrane oriented, lipid reactive oxygen species (L-ROS) (45). Aside from GPX4, other glutathione metabolism related genes, such as *GSH* and *GSR* are also involved in anti-oxidation defense. Cancer cells with acquired drug resistance were reported to have increased cellular GSH levels (46). Lower levels of endogenous ROS and higher levels of antioxidants and GSH were found in temozolomide (TMZ)-resistant glioblastoma cells (47) and silencing the GSH biosynthesis pathway triggered ferroptosis in clear cell carcinoma (48). Thus, modulation of redox homeostasis by GSH/GSR appears to be an important key modulating sensitivity of cancer cells to chemotherapy (47). Interestingly, in our study, the expression of glutathione metabolism-related genes *GSS*, *GSR*, *GPX2*, *IDH* were directly correlated with expression of *FZD7*.

Lastly, our results shed light on a potential mechanism explaining the connection between *FZD7* and activation of the glutathione regulatory machinery. A recent study reported that expression of GPX4 and of other genes involved in glutathione metabolism are regulated transcriptionally by *Tp63* (21). *Tp63* (along with p53 and p73) belongs to the *Tp53* family (49). *TP63* regulates the self-renewal of progenitor cells in epithelial tissues through its by-product *Np63*, which has dominant-negative effects on other p53 family isoforms and exerts tumorigenic functions (34). Unlike *Tp53*, inactivated in a majority of human cancers, including OC, p63 is rarely mutated or inactivated. Overexpression of *Tp63* was associated with poor survival in OC (49, 50), similar to our findings exploring the TCGA database. *Tp63* was shown to regulate the expression of *FZD7* and enhance Wnt signaling in mammary tissue (49). A putative crosstalk between Wnt/ β catenin pathway and *Np63*, the *TP63* isoform lacking the N-terminus domain, was reported in skin, hair follicles, mammary glands and limb buds during development (41). We observed a similar direct and strong correlation between *TP63* and *FZD7* expression in OC cells, supporting that expression of this receptor is regulated by this TF. Furthermore, GPX4 expression, increased in *FZD7* overexpressing cells, was downregulated by *Tp63* knockdown, supporting this mechanism.

In all, our results propose *FZD7* as a new marker for cancer cell populations likely to survive exposure to platinum, enriched in anti-oxidant response mechanisms. These rare cells responsible for disease relapse after chemotherapy, share stemness features and are susceptible to eradication through ferroptosis. Our data provide compelling evidence that targeting Pt-T *FZD7*(+) cells by inducing ferroptosis is effective and could represent a new strategy in a disease of high unmet need.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments:

This research was supported by funding from the Ovarian Cancer Research Alliance, the National Cancer Institute (R01-CA224275), and the Diana Princess of Wales endowed Professorship from the Lurie Cancer Center to DM. Tumor specimens were procured through the Tissue Pathology Core and sequencing was performed in the NUSeq Core supported by NCI CCSG P30 CA060553 awarded to the Robert H Lurie Comprehensive Cancer Center. Flow cytometry analyses were performed in the Northwestern University – Flow Cytometry Core Facility supported by Cancer Center Support Grant NCI CA060553. This research was supported in part through the computational resources and staff contributions provided for the Quest high performance computing facility at Northwestern University which is jointly supported by the Office of the Provost, the Office for Research, and Northwestern University Information Technology.

References:

1. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, et al. Advanced epithelial ovarian cancer: 1998 consensus statements. *Ann Oncol.* 1999;10 Suppl 1:87–92.
2. Tummala MK, and McGuire WP. Recurrent ovarian cancer. *Clin Adv Hematol Oncol.* 2005;3(9):723–36. [PubMed: 16224447]
3. Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. *Nature.* 2017;551(7679):247–50. [PubMed: 29088702]
4. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. *Cell.* 2010;141(1):69–80. [PubMed: 20371346]
5. Liao BB, Sievers C, Donohue LK, Gillespie SM, Flavahan WA, Miller TE, et al. Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. *Cell Stem Cell.* 2017;20(2):233–46 e7. [PubMed: 27989769]
6. Wang Y, Cardenas H, Fang F, Condello S, Taverna P, Segar M, et al. Epigenetic targeting of ovarian cancer stem cells. *Cancer Res.* 2014;74(17):4922–36. [PubMed: 25035395]
7. Wang Y, Zong X, Mitra S, Mitra AK, Matei D, and Nephew KP. IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells. *JCI Insight.* 2018;3(23).
8. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. *Cancer Res.* 2008;68(11):4311–20. [PubMed: 18519691]
9. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. *Cancer research.* 2011;71(11):3991–4001. [PubMed: 21498635]
10. Nguyen LV, Vanner R, Dirks P, and Eaves CJ. Cancer stem cells: an evolving concept. *Nature reviews Cancer.* 2012;12(2):133–43. [PubMed: 22237392]
11. Nwani NG, Condello S, Wang Y, Swetzig WM, Barber E, Hurley T, et al. A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer. *Cancers (Basel).* 2019;11(4).
12. Shi X, Zhang Y, Zheng J, and Pan J. Reactive oxygen species in cancer stem cells. *Antioxid Redox Signal.* 2012;16(11):1215–28. [PubMed: 22316005]
13. Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. *Cancer Cell.* 2013;24(6):751–65. [PubMed: 24332043]
14. Dong R, Qiang W, Guo H, Xu X, Kim JJ, Mazar A, et al. Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma. *J Hematol Oncol.* 2016;9(1):92. [PubMed: 27655386]
15. Hu Y, and Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. *J Immunol Methods.* 2009;347(1–2):70–8. [PubMed: 19567251]
16. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics.* 2013;29(1):7.

17. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics*. 2009;25(16):2078–9. [PubMed: 19505943]
18. Anders S, Pyl PT, and Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. *Bioinformatics*. 2015;31(2):166–9. [PubMed: 25260700]
19. Robinson MD, McCarthy DJ, and Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics*. 2010;26(1):139–40. [PubMed: 19910308]
20. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences of the United States of America*. 2005;102(43):15545–50. [PubMed: 16199517]
21. Wang GX, Tu HC, Dong Y, Skanderup AJ, Wang Y, Takeda S, et al. DeltaNp63 Inhibits Oxidative Stress-Induced Cell Death, Including Ferroptosis, and Cooperates with the BCL-2 Family to Promote Clonogenic Survival. *Cell Rep*. 2017;21(10):2926–39. [PubMed: 29212036]
22. Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, et al. In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. *Br J Cancer*. 2012;106(12):1967–75. [PubMed: 22596241]
23. Asad M, Wong MK, Tan TZ, Choolani M, Low J, Mori S, et al. FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway. *Cell Death Dis*. 2014;5:e1346. [PubMed: 25032869]
24. Merle P, Kim M, Herrmann M, Gupte A, Lefrancois L, Califano S, et al. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. *J Hepatol*. 2005;43(5):854–62. [PubMed: 16098625]
25. Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. *Cancer research*. 2009;69(16):6381–6. [PubMed: 19654294]
26. McMillen BD, Aponte MM, Liu Z, Helenowski IB, Scholtens DM, Buttin BM, et al. Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma. *Mod Pathol*. 2012;25(12):1644–53. [PubMed: 22790015]
27. Gedye C, Sirskyj D, Lobo NC, Meens J, Hyatt E, Robinette M, et al. Cancer stem cells are underestimated by standard experimental methods in clear cell renal cell carcinoma. *Sci Rep*. 2016;6:25220. [PubMed: 27121191]
28. Liang H, Van Remmen H, Frohlich V, Lechleiter J, Richardson A, and Ran Q. Gpx4 protects mitochondrial ATP generation against oxidative damage. *Biochem Biophys Res Commun*. 2007;356(4):893–8. [PubMed: 17395155]
29. Maiorino M, Conrad M, and Ursini F. GPx4, Lipid Peroxidation, and Cell Death: Discoveries, Rediscoveries, and Open Issues. *Antioxid Redox Signal*. 2018;29(1):61–74. [PubMed: 28462584]
30. Pan X, Lin Z, Jiang D, Yu Y, Yang D, Zhou H, et al. Erastin decreases radioresistance of NSCLC cells partially by inducing GPX4-mediated ferroptosis. *Oncol Lett*. 2019;17(3):3001–8. [PubMed: 30854078]
31. Seibt TM, Proneth B, and Conrad M. Role of GPX4 in ferroptosis and its pharmacological implication. *Free Radic Biol Med*. 2019;133:144–52. [PubMed: 30219704]
32. Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. *Nat Commun*. 2019;10(1):1617. [PubMed: 30962421]
33. Sui X, Zhang R, Liu S, Duan T, Zhai L, Zhang M, et al. RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer. *Front Pharmacol*. 2018;9:1371. [PubMed: 30524291]
34. Ruptier C, De Gasperis A, Ansieau S, Granjon A, Taniere P, Lafosse I, et al. TP63 P2 promoter functional analysis identifies beta-catenin as a key regulator of DeltaNp63 expression. *Oncogene*. 2011;30(46):4656–65. [PubMed: 21643019]
35. Integrated genomic analyses of ovarian carcinoma. *Nature*. 2011;474(7353):609–15. [PubMed: 21720365]

36. Pesse T, Flanagan D, and Vincan E. Frizzled7: A Promising Achilles' Heel for Targeting the Wnt Receptor Complex to Treat Cancer. *Cancers (Basel)*. 2016;8(5).
37. King TD, Zhang W, Suto MJ, and Li YH. Frizzled7 as an emerging target for cancer therapy. *Cell Signal*. 2012;24(4):846–51. [PubMed: 22182510]
38. Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan YC, et al. FZD7 has a critical role in cell proliferation in triple negative breast cancer. *Oncogene*. 2011;30(43):4437–46. [PubMed: 21532620]
39. Wu W, Dang S, Feng Q, Liang J, Wang Y, and Fan N. MicroRNA-542–3p inhibits the growth of hepatocellular carcinoma cells by targeting FZD7/Wnt signaling pathway. *Biochem Biophys Res Commun*. 2017;482(1):100–5. [PubMed: 27815069]
40. Ueno K, Hiura M, Suehiro Y, Hazama S, Hirata H, Oka M, et al. Frizzled-7 as a potential therapeutic target in colorectal cancer. *Neoplasia*. 2008;10(7):697–705. [PubMed: 18592008]
41. Simmons GE, Pandey S, Nedeljkovic-Kurepa A, Saxena M, Wang A, and Pruitt K. Frizzled 7 Expression Is Positively Regulated by SIRT1 and beta-Catenin in Breast Cancer Cells. *Plos One*. 2014;9(6).
42. Condello S, Sima L, Ivan C, Cardenas H, Schiltz G, Mishra RK, et al. Tissue Transglutaminase Regulates Interactions between Ovarian Cancer Stem Cells and the Tumor Niche. *Cancer Research*. 2018;78(11):2990–3001. [PubMed: 29510995]
43. Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, et al. N(6)-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance. *Cancer research*. 2019;79(11):2812–20. [PubMed: 30967398]
44. Yu H, Guo P, Xie X, Wang Y, and Chen G. Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. *J Cell Mol Med*. 2017;21(4):648–57. [PubMed: 27860262]
45. Forcina GC, and Dixon SJ. GPX4 at the Crossroads of Lipid Homeostasis and Ferroptosis. *Proteomics*. 2019;19(18):e1800311. [PubMed: 30888116]
46. Chen HH, and Kuo MT. Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. *Met Based Drugs*. 2010;2010.
47. Zhu Z, Du S, Du Y, Ren J, Ying G, and Yan Z. Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis. *J Neurochem*. 2018;144(1):93–104. [PubMed: 29105080]
48. Miess H, Dankworth B, Gouw AM, Rosenfeldt M, Schmitz W, Jiang M, et al. The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. *Oncogene*. 2018;37(40):5435–50. [PubMed: 29872221]
49. Chakrabarti R, Wei Y, Hwang J, Hang X, Andres Blanco M, Choudhury A, et al. DeltaNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. *Nat Cell Biol*. 2014;16(10):1004–15, 1–13.
50. Marchini S, Marabese M, Marrazzo E, Mariani P, Cattaneo D, Fossati R, et al. Delta Np63 expression is associated with poor survival in ovarian cancer. *Annals of Oncology*. 2008;19(3):501–7. [PubMed: 17998283]

Significance:

Frizzled-7 marks platinum-tolerant cancer cells harboring stemness features and altered glutathione metabolism that depend on GPX4 for survival and are highly susceptible to ferroptosis.




Figure 1. Stemness and ferroptosis signatures are enriched in Pt-T OC cells. (A) Representative FACS side scatter analysis of the ALDH(+) population (left), and percentage (mean ± SD, n=5) of ALDH(+) cells (right) in parental (WT), cisplatin tolerant (CDDP), and carboplatin tolerant (Carbo) SKOV3 cells. (B) Representative images (top), and numbers (mean ± SD, n=4) of spheroids (bottom) formed by 1000 parental (WT), CDDP, and carboplatin tolerant (Carbo) SKOV3 cells after 7 days of culture under non-attachment conditions. (C) mRNA levels (fold-change ± SD, n=3) of stemness-related TFs (*Sox2*, *Oct4* and *Nanog*) measured by real-time RT-PCR in CDDP and Carbo tolerant vs. parental SKOV3 cells (WT). (D) GSEA shows upregulated stemness pathway (Stem Cell_UP) in SKOV3 CDDP-tolerant vs. parental cells (FDR=3.22E-04). (E, F) FACS side scatter analysis of percentage of ALDH(+) cells (E), and fold-change (mean ± SD, n=3) *ALDH1A1*, *Nanog*, and *Oct4* mRNA expression levels (F) in OVCAR3 xenografts treated with PBS (Ctrl) or carboplatin (Carbo). (G) Hierarchical clustering heatmap for DEG

(FDR<0.05) ferroptosis-related genes in SKOV3_CDDP vs. control cells (n=3 replicates/group). **(H)** Representative pictures of a colony formation assay (left), and numbers (mean \pm SD, n=3) of colonies (right) developed from 4000 cells isolated from Pt-R human tumors treated with DMSO (Ctrl), ML210 (500nM), DFOA (800nM), or ML210 plus DFOA for 24 hours. **(I)** Fluorescence histograms (top), and mean (\pm SD, n=3) fluorescence (bottom) of BODIPY 581/591-C11 staining show lipid peroxidation in SKOV3 and OVCAR5 parental (WT) cells and cisplatin tolerant (CDDP) cells treated with DMSO or ML210 (1 μ M) for 20 hours. **(J)** Survival curves for WT, cisplatin tolerant (CDDP) and carboplatin tolerant (Carbo) SKOV3 cells in response to cisplatin (left) or GPX4 inhibitor ML210 (right). Cisplatin and ML210 IC₅₀ values are shown. **(K-L)** Survival curves of cells from primary HGSOC tumors treated with cisplatin (left), or GPX4 inhibitor ML210 (right). IC₅₀ for cisplatin and ML210 are shown. For all comparisons: *P<0.05, **P<0.01, ***P<0.001.




Figure 2. Frizzled 7 (FZD7) is upregulated in Pt-T OCs.

(A) Fold-change (mean \pm SD, $n=3$) of *FZD7* mRNA expression levels measured by real-time RT-PCR in cisplatin tolerant (CDDP) compared with parental OVCAR3, OVCAR5, SKOV3 cells. (B) Western blotting for FZD7 in parental and Pt-T SKOV3, OVCAR5 and OVCAR3 cells and Pt-T (-CDDP). Quantification shows fold change of FZD7 expression ($n=3$ experiments). (C-D) *FZD7* mRNA expression levels (mean fold-change \pm SD, $n=3$) (C), and FZD7 protein levels measured by western blotting (D; including quantification in 3 experiments) in Pt-R PEO4 vs. PEO1 cells. (E) Fold-change (mean \pm SD) of *FZD7* mRNA levels in carboplatin-treated (Carbo) and control (Ctrl) SKOV3 (E) and OVCAR3 (F) xenografts ($n=3$ per group). (G) FACS side scatter analysis (left) and average (\pm SD, $n=3$) of FZD7(+) cells dissociated from HGSOc tumors. (H) FACS side scatter analysis of FZD7(+) cells (left), and percentage (mean \pm SD, $n=3$) of FZD7(+) cells (right) in WT and Pt-T SKOV3, OVCAR5 and COV362 cells. (I) NSG mice carrying PDX received

carboplatin (15mg/kg weekly) to induce platinum tolerance. Arrows indicate carboplatin treatment. Mean volumes (\pm SD) are shown (n=5). **(J)** Mean fold change (\pm SD, n=5) for *Sox2*, *Nanog*, *Oct4*, *ALDH1A*, and *ALDH1A2* mRNA expression levels in Pt-T vs. control PDXs. **(K, L)** Mean fold-change of *FZD7* mRNA levels (K), and representative images of *FZD7* IHC staining (L) in Pt-T vs. control PDXs (Ctrl). **(M)** *FZD7* IHC staining and H-scores (mean \pm SD) (right) in sections of fallopian tube (n=6), chemo-naïve OC tumors (n=117) and Pt-T tumors (n=23) included in two tissue microarrays. For all comparisons: *P< 0.05, **P<0.01, and ***P<0.001.




Figure 3. Functional role of FZD7 in OC cells.

(A) *FZD7* mRNA levels (mean fold-change \pm SD, $n=3-4$) in FZD7 (+) and FZD7 (-) cells FACS selected from SKOV3, OVCAR5, and COV362 cells and HGSOc tumors. (B-D) Cell viability (mean fold-change \pm SD, $n=4$) of FZD7(+) and FZD7(-) cells from OVCAR5 ($n=3$) (B), SKOV3 ($n=3$) (C) or COV362 ($n=4$) (D) cells, plated, treated with the indicated doses of CDDP for 24 hours, and cultured for additional three days. (E, F) Representative pictures and numbers (mean \pm SD, $n=4-5$) of spheroids formed after 7 days of culture by FZD7(+) and FZD7(-) cells FACS sorted from SKOV3 (E) and OVCAR5 (F) OC cells. Spheroids were counted or cell numbers were estimated by CellTiter-Glo 3D cell viability assay. (G-I) mRNA levels (fold-change \pm SD) of *Nanog* in FZD7(+) compared with FZD7(-) cells from SKOV3 (G) ($n=3$), OVCAR5 (H) ($n=8$) and COV362 (I) ($n=3$) cells. For all comparisons: * $P<0.05$, ** $P<0.01$, *** $P<0.001$.




Figure 4. FZD7 regulates stemness characteristics.

(A) (Left) *FZD7* mRNA levels (mean fold-change ± SD, n=3) in SKOV3 cells transduced with shRNAs targeting *FZD7* (shFZD7) vs. control shRNAs (shctrl). (Right) Numbers of spheroids (mean ± SD, n=4) formed by 2,000 shFZD7 or shctrl SKOV3 cells cultured for 14 days and counted under a microscope. (B) *FZD7* mRNA expression levels (mean fold-change ± SD, n=4; left) and numbers of spheroids (n=5; right) in OVCAR5 cells transduced with shRNAs directed at *FZD7* (shFZD7) vs. control shRNAs (shctrl). Cell viability assessed numbers of cells growing as spheroids using the CellTiter-Glo kit. (C) *Sox2* and *Nanog* mRNA levels (mean fold-change ± SD, n=3–4) in OVCAR5 cells transduced with shFZD7 vs. shctrl. (D) *FZD7* mRNA levels (mean fold-change ± SD, n=3) in Pt-R primary HGSOE cells transduced with shRNAs targeting *FZD7* (shFZD7) vs. control shRNA (shctrl). (E) *ALDH1A1* mRNA levels (mean fold-change ± SD, n = 3) in primary tumor cells transduced with shFZD7 cells vs. shctrl. (F) Average fold-change (± SD, n = 3) of

FZD7 mRNA in SKOV3 (left) and OVCAR5 (right) cells transfected with FZD7-pcDNA3.1 vs. empty vector (ctrl). **(G)** Spheroid formation estimated with a CellTiter-Glo viability kit (bottom) from 1,000 ctrl and FZD7 expressing SKOV3 or OVCAR5 cells (described in F) and cultured for 7 days (n =4–5 per group). **(H-J)** Effects of CDDP on cell survival measured by CCK8 assays in SKOV3_shctrl and SKOV3_shFZD7 **(H)**, SKOV3 cisplatin tolerant cells (SKOV3_CDDP) transduced with shRNAs targeting FZD7 (shFZD7_1, _2) or control shRNA **(I)**, and SKOV3 cells transfected with FZD7-pcDNA3.1 (FZD7) or empty vector (Ctrl) **(J)**. Cells were treated with cisplatin for 24 hours and cultured for additional 3 days (n=3–4). Cisplatin IC₅₀ value is shown. **(K)** Days to tumor initiation (mean ± SD, n = 10) of sq xenografts induced by 2×10⁶ shctrl and shFZD7 transduced OVCAR5 cells. **(L)** FACS side scatter analysis of ALDH(+) cells (top), and percentage (mean ± SD, n=3) of ALDH(+) cells (bottom) from cell suspensions generated from OVCAR5_shctrl and OVCAR5_shFZD7 xenografts. **(M)** Numbers (mean ± SD, n=5) of spheroids (bottom) formed during 14 days by 1000 cells derived from cell suspensions from OVCAR5_shctrl or OVCAR5_FZD7 xenografts. **(N-O)**. *In vivo* limited dilution assay used serially diluted numbers (2,500, 5,000, and 10,000) of OVCAR5_shctrl and shFZD7 cells injected sq into nude mice (n=4 replicates per group). **(N)** Average tumor weights (± SD) are shown (for the 10,000 cells group). **(O)** Stem cell frequencies were calculated by using the Extreme Limiting Dilution Analysis (<http://bioinf.wehi.edu.au/software/elda/>; *p* = 0.000254). **(P)** A Venn diagram shows the number overlapping and unique DEGs between OVCAR5-derived OCSCs (ALDH+CD133+) versus non-OCSCs (ALDH-CD133-), OVCAR5 cisplatin tolerant (CDDP-R) vs. parental (WT), and FZD7(+) versus FZD7(-) OVCAR5 cells (FDR < 0.05). ALDH+CD133/ALDH-CD133- and FZD7+/FZD7- cells were sorted by FACS. For all comparisons: **P*<0.05, ***P*<0.01, ****P*<0.001.




Figure 5. FZD7 regulates GPX4 and intracellular redox states.

(A) Fold-change (mean \pm SD, n=3–4) of *GPX4 mRNA* levels in FZD7(+) vs. FZD7(-) cells FACS sorted from SKOV3, OVCAR5, COV362 cells and cell suspensions from HGSOc tumors. (B) Fold-change (mean \pm SD, n=4) of *GPX4 mRNA* expression levels in OVCAR5 cells transduced with shRNAs targeting *FZD7* (shFZD7) vs. control shRNAs (shctrl). (C) Western blotting for FZD7, GPX4 and GAPDH in SKOV3 and OVCAR5 cells stably transduced with shctrl and shFZD7. Quantification shows fold change of FZD7 and GPX4 expression across 3 experiments. (D-E) *GPX4 mRNA* expression levels (fold-change \pm SD, n = 3) in SKOV3 Pt-T cells (CDDP) (D), and Pt-R primary human HGSOc cells (E) transduced with shRNAs directed at *FZD7* (shFZD7) vs. control shRNAs (shctrl). (F, G) Average fold-change (\pm SD, n=3) of *GPX4 mRNA* levels in SKOV3 (F) and OVCAR5 (G) cells transfected with FZD7-pcDNA3.1 vs. empty vector (ctrl). (H) Western blotting for FZD7, GPX4 and GAPDH in OVCAR5 cells transfected with FZD7-pcDNA3.1 vs. empty vector (ctrl).

vector (ctrl). Quantification shows fold change of FZD7 and GPX4 expression across 3 experiments. **(I-K)** *GPX4 mRNA* expression (mean fold-change \pm SD) in SKOV3 and OVCAR5 Pt-T (CDDP) vs. parental cells (WT) **(I)**; n = 3/group). **(J)** SKOV3 and OVCAR5 xenografts (n=3 per group; **J**) and PDX tumors **(K)**; n=5 per group) treated with PBS (Ctrl) or carboplatin. **(L)** Representative images of GPX4 IHC staining in sections of control (Ctrl) and Pt-T PDXs. **(M)** Representative pictures of GPX4 IHC (left) and H-scores (mean \pm SD) (right) in sections of fallopian tube (n = 6) and Pt-R HGSOc tumors (n = 23). **(N)** Lipid peroxidation in SKOV3 and OVCAR5 cells transduced with scrambled shRNA (shctrl) or shRNAs targeting *FZD7* (shFZD7) and expressed as average luciferase units/ 3×10^6 cells (\pm SD, n=4) **(O)** Intracellular lipid peroxidation measured in SKOV3 and OVCAR5 cells transfected with FZD7 or control vector (Ctrl) and expressed as average luciferase units/ 3×10^6 cells \pm SD (n=4). For all comparisons: *P<0.5, **P<0.01, ***P<0.001.




Figure 6. FZD7 marks a cell population susceptible to GPX4 inhibitors. (A) Average fold-change (\pm SD, n = 3) in *mRNA* expression levels of selected glutathione metabolism genes in OVCAR5 cells transduced with shRNAs targeting FZD7 (shFZD7) vs. control shRNA (A), and in OVCAR5 cells transfected with FZD7-pcDNA3.1 (FZD7) vs. control vector (Ctrl) (B) (C-D) Viability of FZD7(+) and FZD7(-) cells sorted from OVCAR5 and COV362 (D) cells and treated with DMSO or ML210 (OVCAR5, 2 μ M; COV362, 1 μ M) for 72 hours. Data are presented as average fold-change (\pm SD, n = 4) of absorbance values relative to control. (E) Survival curves of OVCAR5 (left) and SKOV3 (right) cells transduced with control shRNAs (shctrl) or shRNAs targeting *FZD7* (shFZD7) and treated with ML210 for 3 days (n=3–4). ML210 IC₅₀ values are shown below. (F) Survival curves of OVCAR5 (left) and SKOV3 (right) cells transfected with FZD7-pcDNA3.1 or control vector and treated with ML210 for 3 days. ML210 IC₅₀ values are shown below (n=3–4). (G) Images (left) and quantification of intracellular ROS levels

(right) in OVCAR5 cells transfected with control shRNA (shctrl) or shRNA targeting *FZD7* (shFZD7). Data are presented as means (\pm SD) of DCF fluorescence intensity per cell area ($n = 15$). **(H)** Histograms of fluorescence intensity (left) and mean (\pm SD, $n = 3$) (right) of BODIPY 581/591-C11 in OVCAR5 (left) and SKOV3 (right) cells transfected with vector (ctrl), FZD7-pCDNA3.1 (FZD7), control shRNA (shctrl), or shRNAs targeting *FZD7* (shFZD7). **(I, J)** Mean (\pm SD, $n=3$) fluorescence intensity of BODIPY 581/591-C11 show effects of ML210 (1 μ M for 20 hours) on lipid peroxidation levels in SKOV3 **(I)** and OVCAR5 **(J)** cells transfected with empty vector (ctrl), FZD7-pcDNA3.1 (FZD7), control shRNA (shctrl), or shRNA against *FZD7* (shFZD7). **(K)** Intracellular ROS levels in OVCAR5 cells transfected with shctrl and shFZD7 treated with DMSO, ML210 (2 μ M, 24 hours) and ML210 + DFOA (800nM, 24 hours) measured by assessing DCFHDA oxidation. Average intensity per cell area (\pm SD) is shown ($n=15$). For all comparisons: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.




Figure 7. FZD7 regulates GPX4 expression and glutathione metabolism by activating the canonical β catenin/p63 pathway. (A) *P63* mRNA levels (fold-change \pm SD, n=4) in Pt-T PDXs (carbo) vs. controls (Ctrl). (B) *P63* mRNA levels (fold-change \pm SD, n=3–6) in FZD7(+) versus FZD7(–)cells sorted from SKOV3, OVCAR5, and COV362 cell lines, and cell suspensions from human tumors. (C) *P63* mRNA expression levels (fold-change \pm SD, n = 4) in OVCAR5 cells transduced with shRNAs targeting *FZD7* (shFZD7) vs. control shRNA (shctrl). (D) Western blot for β -catenin, P63, and GAPDH in SKOV3 and OVCAR5 cells transduced with shRNAs targeting *FZD7* (shFZD7) or control shRNA (shctrl). Quantification shows fold change of β -catenin and P63 expression across 3 experiments. (E, F) *P63* mRNA levels (fold-change \pm SD, n=3) in OVCAR5 (E) and SKOV3 (F) cells transfected with FZD7 vs. control vector (Ctrl). (G) Western blot for β -catenin, P63, and GAPDH in OVCAR5 cells transfected with control (ctrl) or FZD7-pcDNA3.1 (FZD7). Quantification shows fold change of β -catenin and P63 expression across 3 experiments. (H) Western blot for FZD7, β -catenin, P63, GPX4 and

GAPDH in OVCAR5 cells transfected with shctrl, shFZD7 (**J**) treated with WNT3a (150ng/ul) and/or IWR-1-endo (1 μ M) for 24 hours (n = 2). (**I-K**) *FZD7*(**I**), *P63* (**J**), and *GPX4* (**K**) mRNA expression levels (fold-change \pm SD, n=3–4) in OVCAR5 cells transduced with control shRNAs (Ctrl_shctrl, Ctrl_shP63, FZD7_shctrl) or transfected with FZD7 expression vector and subsequently transduced with shRNA targeting *P63* (FZD7_shP63). For all comparisons: *P<0.05, **P<0.01, ***P<0.001. (**L**) Scatter plot shows the correlation between *P63* and *FZD7 mRNA* expression levels in HGSOc tumors (n=419) profiled in the TCGA database. Pearson correlation coefficients and P-values are shown. (**M**) Kaplan-Meier survival curves for HGSOc patients profiled in the TCGA having high (n=61) or low (n=318) *P63* (*TP63-012*) mRNA expression levels. High or low levels were defined based on statistically determined cutoff point that maximizes absolute value of the standardized two-sample linear rank statistic. (**N**) Model demonstrates the proposed mechanism by which FZD7 engages the anti-oxidant pathway governed by GPX4.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript